Patents by Inventor Rae-Lynn Nesbitt

Rae-Lynn Nesbitt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT POLYPEPTIDES FOR MEMBRANE FUSION AND USES THEREOF
    Publication number: 20230192783
    Abstract: Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.
    Type: Application
    Filed: September 19, 2022
    Publication date: June 22, 2023
    Inventors: Roy Duncan, Eileen Kathryn Clancy, John Lewis, Roberto Justo De Antueno, Rae-Lynn Nesbitt
  • Recombinant polypepties for membrane fusion and uses thereof
    Patent number: 11459362
    Abstract: Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: October 4, 2022
    Assignee: ENTOS PHARMACEUTICALS INC.
    Inventors: Roy Duncan, Eileen Kathryn Clancy, John Lewis, Roberto Justo De Antueno, Rae-Lynn Nesbitt
  • Recombinant Polypepties for Membrane Fusion and Uses Thereof
    Publication number: 20190367566
    Abstract: Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.
    Type: Application
    Filed: January 11, 2019
    Publication date: December 5, 2019
    Inventors: Roy Duncan, Eileen Kathryn Clancy, John Lewis, Roberto Justo De Antueno, Rae-Lynn Nesbitt
  • Recombinant polypeptides for membrane fusion and uses thereof
    Patent number: 10227386
    Abstract: Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: March 12, 2019
    Assignee: Entos Pharmaceuticals Inc.
    Inventors: Roy Duncan, Eileen Kathryn Clancy, John Lewis, Roberto Justo De Antueno, Rae-Lynn Nesbitt
  • RECOMBINANT POLYPEPTIDES FOR MEMBRANE FUSION AND USES THEREOF
    Publication number: 20140314831
    Abstract: Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.
    Type: Application
    Filed: September 29, 2011
    Publication date: October 23, 2014
    Applicant: Innovascreen Inc.
    Inventors: Roy Duncan, John Lewis, Roberto Justo De Antueno, Rae-Lynn Nesbitt, Eileen Kathryn Clancy